deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT00951496

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Sponsor: NRG Oncology

Conditions Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Malignant Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Clear Cell Adenocarcinoma Primary Peritoneal Endometrioid Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Primary Peritoneal Transitional Cell Carcinoma Primary Peritoneal Undifferentiated Carcinoma Stage II Fallopian Tube Cancer AJCC v6 and v7 Stage II Ovarian Cancer AJCC v6 and v7 Stage IIA Fallopian Tube Cancer AJCC v6 and v7 Stage IIA Ovarian Cancer AJCC V6 and v7 Stage IIB Fallopian Tube Cancer AJCC v6 and v7 Stage IIB Ovarian Cancer AJCC v6 and v7 Stage IIC Fallopian Tube Cancer AJCC v6 and v7 Stage IIC Ovarian Cancer AJCC v6 and v7 Stage III Ovarian Cancer AJCC v6 and v7 Stage III Primary Peritoneal Cancer AJCC v7 Stage IIIA Ovarian Cancer AJCC v6 and v7 Stage IIIA Primary Peritoneal Cancer AJCC v7 Stage IIIB Ovarian Cancer AJCC v6 and v7 Stage IIIB Primary Peritoneal Cancer AJCC v7 Stage IIIC Ovarian Cancer AJCC v6 and v7 Stage IIIC Primary Peritoneal Cancer AJCC v7 Stage IV Fallopian Tube Cancer AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7
Interventions Bevacizumab Carboplatin Cisplatin Laboratory Biomarker Analysis Paclitaxel Quality-of-Life Assessment
Updated 33 times since 2017 Last updated: Apr 13, 2021 Started: Aug 11, 2009 Primary completion: Jan 11, 2016 Completion: Jan 11, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Fallopian Tube Clear Cell Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, this trial is completed. The trial is conducted by NRG Oncology and has accumulated 33 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

33 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. May 2021 — Jun 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 28 earlier versions

  1. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  9. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  14. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  15. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  16. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  17. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  18. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  19. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  20. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  21. Apr 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  22. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  23. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  24. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  25. Jul 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  26. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  27. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  28. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Ames, United States , Anchorage, United States , Anderson, United States , Ann Arbor, United States and 308 more locations